Should Doctors Offer Biomarker Testing to Those Afraid to Develop Alzheimer’s Dementia? Applying the Method of Reflective Equilibrium for a Clinical Dilemma

Marthe Smedinga*, Eline M. Bunnik, Edo Richard, Maartje H.N. Schermer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
64 Downloads (Pure)

Abstract

An increasing number of people seek medical attention for mild cognitive symptoms at older age, worried that they might develop Alzheimer’s disease. Some clinical practice guidelines suggest offering biomarker testing in such cases, using a brain scan or a lumbar puncture, to improve diagnostic certainty about Alzheimer’s disease and enable an earlier diagnosis. Critics, on the other hand, point out that there is no effective Alzheimer treatment available and argue that biomarker tests lack clinical validity. The debate on the ethical desirability of biomarker testing is currently polarized; advocates and opponents tend to focus on their own line of arguments. In this paper, we show how the method of reflective equilibrium (RE) can be used to systematically weigh the relevant arguments on both sides of the debate to decide whether to offer Alzheimer biomarker testing. In the tradition of RE, we reflect upon these arguments in light of their coherence with other argumentative elements, including relevant facts (e.g. on the clinical validity of the test), ethical principles, and theories on societal ideals or relevant concepts, such as autonomy. Our stance in the debate therefore rests upon previously set out in-depth arguments and reflects a wide societal perspective.

Original languageEnglish
Pages (from-to)287-297
Number of pages11
JournalJournal of Bioethical Inquiry
Volume19
Issue number2
Early online date19 Mar 2022
DOIs
Publication statusPublished - Jun 2022

Bibliographical note

Funding Information:
This work has received support from the Netherlands Organization for Health Research and Development [grant number 731010012] and the European Union—European Federation of Pharmaceutical Industries and Associations (EU-EFPIA) Innovative Medicines Initiatives 2 Joint Undertaking [grant number 115952]. This publication represents the views of the authors and not necessarily those of the entire latter research consortium.

Publisher Copyright:
© 2022, Journal of Bioethical Inquiry Pty Ltd.

Fingerprint

Dive into the research topics of 'Should Doctors Offer Biomarker Testing to Those Afraid to Develop Alzheimer’s Dementia? Applying the Method of Reflective Equilibrium for a Clinical Dilemma'. Together they form a unique fingerprint.

Cite this